Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye layer thickness may hold key to glaucoma laser outcomes

NCT ID NCT07592923

Knowledge-focused Sponsor: Kazakh Eye Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 21, 2026 · Updated 2 times

Summary

This study looks at whether the thickness of a layer inside the eye (the choroid) can predict how well a gentle laser treatment works for glaucoma. Researchers will measure eye pressure and choroid thickness before and after the laser procedure in 20 adults with glaucoma. The goal is to find a simple marker that helps doctors choose the best treatment for each patient.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Micropulse transscleral cyclophotocoagulation (laser procedure)
What this could lead to
If successful, this could help doctors predict which glaucoma patients will benefit most from micropulse laser treatment, leading to more personalized care.
What could go wrong
This is a very small, early-stage study with only 20 participants. It is designed to gather information, not to prove a new treatment works, so results may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

May 2026

Finished

Aug 2026

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Decision to treat by MP-CPC Laser * Patients diagnosed with Glaucoma * Patients aged 18 years old and above * Glaucoma that is inadequately controlled on medical therapy Exclusion Criteria: * Patients age less than 18 years * Patients unable or unwilling to provide informed consent to participate in the study * Patients potentially unavailable for follow up visits * Patients with significant scleral thinning * Patients with ocular infection, inflammation or intraocular surgery in the study eye 2 months prior to enrollment in the study * Albino patients that have no iris pigmentation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glaucoma

Contacts and locations

Locations

  • Kazakh Eye Research Institute

    Almaty, 050012, Kazakhstan

More trials for these conditions

Other studies related to the condition(s) this trial covers.